Global Molecular Transplant Diagnostics Market to Triple Revenue
By Labmedica International staff writers
Posted on 09 May 2017
Image: The global market for molecular transplant diagnostics is projected to grow at an average annual rate of 9% up to 2021 (Photo courtesy of Kalorama Information).
The global market for molecular transplant diagnostics is estimated to be over USD 300 million and is projected to grow at an average annual rate of 9% up to 2021. These are the latest findings of Kalorama Information, an independent medical market research firm.
Molecular testing technologies are well suited for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, which require histocompatibility between the recipient and donor for successful outcomes. The various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and HSCT or bone marrow transplants; post-transplant monitoring including for transplant rejection is an ancillary testing area. Allogenic HSCT transplantation is a comparatively high growth procedure area in comparison to solid organ transplantation and is a leading area of application for molecular HLA typing.
Over allogenic 9,000 HSCTs and approximately 30,000 solid organ transplants are performed in the US each year, making it the world’s largest market for molecular transplant diagnostics. The large size of the US molecular transplant diagnostics market is sustained by the demand for high resolution molecular HLA typing, including sequencing-based methods. In Europe, over 30,000 solid organ transplants and around 18,000 HSCTs are performed each year with transplant volumes in the region continuing to grow at a faster pace as compared to the US. This is due to the higher number of solid organ transplants and HSCTs being performed in the Eastern European countries and other less mature markets, thereby driving sales of test products.
"Molecular is not ubiquitous, as some forecasters – including us- may have thought a decade ago," said Bruce Carlson, Publisher of Kalorama Information. "It performs well in areas where it is set apart from other technologies. HLA is a value-add area for molecular, and you see that in the growth rate."